Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 3 3Phase 2 3Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 9NIH 4INDUSTRY 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × copanlisib × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT02342665 2023-01-20

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Bayer

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡